Arbutus Pharma | 8-K: FY2026 Q2 Revenue: USD 1.014 M

Revenue: As of FY2026 Q2, the actual value is USD 1.014 M.

EPS: As of FY2026 Q2, the actual value is USD -0.03.

EBIT: As of FY2026 Q2, the actual value is USD -5.125 M.

Financial Position and Cash Flow

As of June 30, 2026, Arbutus Biopharma Corporation reported cash, cash equivalents, and marketable securities totaling $92.6 million, an increase from $91.5 million as of December 31, 2025. The Company received its first payment of approximately $178 million from the Moderna settlement in July 2026. A receivable from Genevant license was reported at $179.373 million as of June 30, 2026, compared to $0 as of December 31, 2025.

For the six months ended June 30, 2026, net cash used in operating activities was - $14.128 million, an improvement from - $29.140 million for the same period in 2025. Net cash from financing activities was $14.767 million for the six months ended June 30, 2026, up from $3.237 million in 2025. Net cash provided by investing activities decreased to $0.538 million for the six months ended June 30, 2026, from $26.960 million in the prior year period.

Revenue

Total revenue for the quarter ended June 30, 2026, was $1.014 million, a significant decrease from $10.739 million for the same period in 2025, primarily due to recognizing $9.6 million of previously deferred revenue in Q2 2025 following a strategic partnership conclusion with Qilu. In Q2 2026, collaboration and license revenue was $0.202 million, license revenue from Genevant was $0.632 million, and non-cash royalty revenue was $0.180 million.

Operating Expenses

Research and development expenses decreased to $2.898 million for the quarter ended June 30, 2026, from $5.498 million in the prior year, driven by cost savings from workforce reduction, discontinuation of in-house scientific research, and lower clinical trial costs. General and administrative expenses increased to $3.867 million for the quarter ended June 30, 2026, from $3.328 million in 2025, mainly due to higher stock compensation expenses. Total operating expenses for the quarter ended June 30, 2026, were $6.978 million, down from $9.251 million in the same period of 2025.

Net Income/Loss and Operational Profit

Arbutus Biopharma Corporation reported a net loss of - $5.143 million for the quarter ended June 30, 2026, or - $0.03 per basic and diluted common share, compared to a net income of $2.523 million, or $0.01 per basic and diluted common share, for the quarter ended June 30, 2025. The loss from operations for Q2 2026 was - $5.964 million, a shift from an income of $1.488 million in Q2 2025.

Outstanding Shares

As of June 30, 2026, Arbutus Biopharma Corporation had 197.6 million common shares issued and outstanding, along with 8.6 million stock options and unvested restricted stock units outstanding. The weighted average number of common shares basic for Q2 2026 was 197,470,724, compared to 191,551,282 for Q2 2025.

Outlook / Guidance

Arbutus Biopharma Corporation anticipates returning up to approximately $230 million in capital to shareholders starting in Q3 2026 through share repurchases, subject to board approval. The Company also expects to receive a material dividend from Genevant in the third quarter of 2026. Furthermore, Arbutus plans to integrate FDA feedback into the final Phase 2b protocol for imdusiran, which has demonstrated functional cure in 10 chronic hepatitis B patients to date.